40th week of 2017 patent applcation highlights part 11 |
Patent application number | Title | Published |
20170281615 | EXTENDED RELEASE, ABUSE DETERRENT DOSAGE FORMS - Extended release, abuse deterrent dosage forms comprising crush-resistant controlled-release particles that provide abuse deterrent properties to the dosage forms. The crush-resistant controlled-release particles, which comprise plastic/elastic polymers and at least one active pharmaceutical ingredient (API) or a pharmaceutically acceptable salt thereof, are prepared by a hot melt extrusion process. | 2017-10-05 |
20170281616 | MORPHINAN COMPOUNDS - This invention relates to novel morphinan compounds and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a σ | 2017-10-05 |
20170281617 | COMPOSITIONS AND METHODS FOR INCREASING THE METABOLIC LIFETIME OF DEXTROMETHORPHAN AND RELATED PHARMACODYNAMIC EFFECTS - This disclosure relates to methods administering various compounds in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and bupropion, hydroxybupropion, erythrohydroxybupropion, threohydroxybupropion, or a metabolite or prodrug of any of these compounds are also disclosed | 2017-10-05 |
20170281618 | INJECTABLE FLOWABLE COMPOSITION COMPRISING BUPRENORPHINE - The present invention is directed to a buprenorphine sustained release delivery system capable of delivering buprenorphine, a metabolite, or a prodrug thereof for a duration of about 14 days to about 3 months. The buprenorphine sustained release delivery system includes a flowable composition and a solid implant for the sustained release of buprenorphine, a metabolite, or a prodrug thereof. The implant is produced from the flowable composition. The buprenorphine sustained release delivery system provides in situ 1-month and 3-month release profiles characterized by an exceptionally high bioavailability and minimal risk of permanent tissue damage and typically no risk of muscle necrosis. | 2017-10-05 |
20170281619 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH A SELECTIVE BCL-2 INHIBITOR - The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective BCL-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer. | 2017-10-05 |
20170281620 | CHEMICALLY AND METABOLICALLY STABLE DIPEPTIDE POSSESSING POTENT SODIUM CHANNEL BLOCKER ACTIVITY - A very stable, selective and renally safe sodium channel blocker represented by the formula: | 2017-10-05 |
20170281621 | SUBSTITUTED PYRIDAZINES AS SKELETAL MUSCLE MODULATORS - Provided are compounds of Formula I: | 2017-10-05 |
20170281622 | DERIVATIVES OF MACROCYCLIC N-ARYL-2-AMINO-4-ARYL-PYRIMIDINE POLYETHERS AS INHIBITORS OF FTL3 AND JAK - The present invention relates to a compound with the following formula: formula (I) or a salt and/or a pharmaceutically acceptable solvate thereof, in particular for use as a drug, in particular in the treatment of cancer, as well as to the pharmaceutical compositions that contain same and to the methods for preparing same. | 2017-10-05 |
20170281623 | SOLID FORMS OF AN EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR - The present invention provides a solid form and composites thereof, which are useful as an inhibitor of EGFR kinases and which exhibit desirable characteristics for the same. | 2017-10-05 |
20170281624 | COMBINATION THERAPIES OF ALK INHIBITORS - A method of treating a cancer in a subject is disclosed, comprising administering to the subject an immunomodulator and a second therapeutic agent, wherein: (i) the immunomodulator is chosen from one or more of: an activator of a costimulatory molecule or an inhibitor of an immune checkpoint molecule, and (ii) the second therapeutic agent is LDK378, thereby treating the cancer. | 2017-10-05 |
20170281625 | METHODS OF TREATING HEART FAILURE - Methods of treating heart failure include administering to a subject having heart failure an effective amount of a triazole compound that is an agonist of the APJ receptor, a pharmaceutically acceptable salt of the compound, or a mixture thereof. Compounds particularly useful in such methods are provided herein. | 2017-10-05 |
20170281626 | PYRIMIDINEDIONE COMPOUNDS - Provided are novel pyrimidine dione compounds and pharmaceutically acceptable salts thereof, that are useful for the treatment of hypertrophic cardiomyopathy (HCM) and conditions associated with left ventricular hypertrophy or diastolic dysfunction. The synthesis and characterization of the compounds and pharmaceutically acceptable salts thereof, are described, as well as methods for treating HCM and other forms of heart disease. | 2017-10-05 |
20170281627 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS - The present disclosure relates generally to toll like receptor modulator compounds, such as diamino pyrido[3,2 D] pyrimidine compounds and pharmaceutical compositions which, among other things, modulate toll-like receptors (e.g. TLR-8), and methods of making and using them. | 2017-10-05 |
20170281628 | MOLECULAR TARGETS FOR THE TREATMENT OF WOUNDS, IN PARTICULAR CHRONIC WOUNDS - The present invention relates to a therapeutic compound comprising: an agent that inhibits the activity of at least one gene selected from the group consisting of MAF, MEOX2, SIX2 and homologues thereof having at least 50% identity with said genes and/or an agent that enhances the activity of at least one gene selected from the group consisting of CREBS, E2F1, EGR2, HIC1, IRF7, JUN, MYC, SRF, STAT4, TCF4, FOXS1, GLI1, SOX9 and homologues thereof having at least 50% identity with said gene for use in the treatment of wounds, preferably chronic wounds. | 2017-10-05 |
20170281629 | DOSING REGIMEN FOR MISSED DOSES FOR LONG-ACTING INJECTABLE PALIPERIDONE ESTERS - The present application provides a method for treating patients in need of psychiatric treatment, wherein said patient is being treated with the 3-month formulation of paliperidone palmitate and fails to take the next scheduled dose of the 3-month formulation of paliperidone palmitate. | 2017-10-05 |
20170281630 | METHOD OF TREATMENT AND COMPOSITIONS COMPRISING A DUAL PI3K DELTA-GAMMA KINASE INHIBITOR AND A CORTICOSTEROID - This present disclosure relates to a method of treating autoimmune, respiratory and/or inflammatory diseases or conditions, e.g., asthma, COPD, rheumatoid arthritis and idiopathic Pulmonary Fibrosis (IPF). The method comprises administering a dual PI3K delta and gamma inhibitor and a corticosteroid. The present invention also relates to pharmaceutical compositions containing a dual PI3K delta and gamma inhibitor and a corticosteroid. | 2017-10-05 |
20170281631 | PHARMACEUTICAL FORMULATION OF PALBOCICLIB AND A PREPARATION METHOD THEREOF - The present invention belongs to the pharmaceutical field, and in particular, it relates to a pharmaceutical formulation of palbociclib and a preparation method thereof. The pharmaceutical formulation comprises palbociclib, an acidic auxiliary material, and optionally a hydrophilic high-molecular material, which has better solubility and in vitro dissolution property as compared with the conventional formulation and can be used for enhancing in vivo absorption and bioavailability of palbociclib. | 2017-10-05 |
20170281632 | METHODS OF TREATING PEDIATRIC CANCERS - A method of treating a pediatric cancer in a subject in need thereof. The method includes administering to the subject a therapeutically effective amount of (S)—N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide, or a pharmaceutically acceptable salt thereof, or a combination thereof. | 2017-10-05 |
20170281633 | SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH - Provided herein are methods for treating or preventing a cancer, including solid tumors and hematological cancers, comprising administering an effective amount of aminopurine compounds of formula (I), and compositions comprising an effective amount of such compounds. | 2017-10-05 |
20170281634 | MINDFULLNESS-INCREASING COMPOSITION AND METHOD OF USE - Disclosed is a mindfulness-increasing composition and method of use. A mixture, some variations of which include 5-amino-3-phenylbuteric acid (phenibut), L-theanine, and 5-hydroxytryptophan (5-HTP), increases focus, mental and physical performance, and calmness while decreasing anxiety and promoting increased mental and physical performance and overall sense of wellbeing through an increased level of mindfulness. The mindfulness-increasing composition also comprises a proprietary neurosupportive blend for optimization of mental and physical performance beneficial to general overall health. An excipient delivery system to provide bioavailability of a palatable, convenient, orally-ingested composition is included. Additionally, methods of use are described, allowing for effective, safe, and convenient use of a mindfulness-increasing composition comprising phenibut. | 2017-10-05 |
20170281635 | FUSED HETEROCYCLIC ORGANIC COMPOUNDS AND USES THEREOF - This disclosure provides compounds, pharmaceutical formulations, and related methods of use for the treatment of defects of cholesterol homeostasis including lysosomal storage disorders such as Niemann-Pick Type C disease. | 2017-10-05 |
20170281636 | ANTIVIRAL THERAPY - The present invention relates to combinations of compounds comprising HIV integrase inhibitors and other therapeutic agents. Such combinations are useful in the inhibition of HIV replication, the prevention and/or treatment of infection by HIV, and in the treatment of AIDS and/or ARC | 2017-10-05 |
20170281637 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors - There is provided a compound of formula I: | 2017-10-05 |
20170281638 | A SALT OF CEPHALOSPORIN DERIVATIVE, ITS CRYSTALLINE SOLID AND A METHOD OF MANUFACTURING THEREOF - The present invention provides an acid addition salt or a sodium salt of a compound represented by the formula (IA): | 2017-10-05 |
20170281639 | PREPARATION CONTAINING CEPHALOSPORIN HAVING A CATECHOL MOIETY - The present invention relates to a stable pharmaceutical composition comprising a compound represented by formula (I), its pharmaceutically acceptable salt or a solvate thereof. | 2017-10-05 |
20170281640 | Pharmaceutical Compositions Containing a Muscle Relaxant and a Nonsteroidal Anti-Inflammatory Drugs (NSAID) - Provided herein is a stable pharmaceutical composition including meloxicam and methocarbamol in the form of granules, including a meglumine and sodium citrate complex to improve solubility. The pharmaceutical compositions are administered simultaneously and are kept separated in the pharmaceutical form that is administered. Also provided herein are methods for the treatment of disorders associated with muscle, skeletal muscle, and pain. | 2017-10-05 |
20170281641 | CYCLIC UREA COMPOUNDS AS TROPOMYOSIN-RELATED KINASE (TRK) iNHIBITORS - Tropomyosin-related kinase inhibitors (Trk inhibitors) are small molecule compounds useful in the treatment of disease. Trk inhibitors can be used as pharmaceutical agents and in pharmaceutical compositions. Trk inhibitors are useful in the treatment of inflammatory diseases, autoimmune disease, defects of bone metabolism and/or cancer, and are particularly useful in the treatment of osteoarthritis (OA), pain, and pain associated with OA. Trk inhibitors are also useful for inhibiting tropomyosin-related kinase A (TrkA), tropomyosin-receptor kinase B (TrkB), tropomyosin-receptor kinase C (TrkC), and/or c-FMS (the cellular receptor for colony stimulating factor-1 (CSF-1)). | 2017-10-05 |
20170281642 | METHODS OF TREATING ACUTE MYELOID LEUKEMIA OR ACUTE LYMPHOID LEUKEMIA USING PHARMACEUTICAL COMPOSITIONS CONTAINING THIENOTRIAZOLODIAZEPINE COMPOUNDS - A method of treating acute myeloid leukemia or acute lymphoid leukemia in a mammal comprising the step of: administering a pharmaceutically acceptable amount of a thienotriazolodiazepine compound represented by the following Formula (1): wherein R | 2017-10-05 |
20170281643 | COMPOUNDS AND METHODS FOR MODULATING FRATAXIN EXPRESSION - The present technology relates to compositions and methods for modulating expression of genes, which include a target oligonucleotide sequence, such as repeats of a particular oligonucleotide sequence containing 3 to 10 nucleotides. In particular aspects, the present technology relates to agents having a formula A-L-B, wherein -L- is a linker; A- is a Brd4 binding moiety; and -B is a nucleic acid binding moiety, such as a polyamide or complementary oligonucleotide, that specifically binds to the target oligonucleotide sequence. | 2017-10-05 |
20170281644 | FORMULATIONS OF TESTOSTERONE AND METHODS OF TREATMENT THEREWITH - The present disclosure relates to novel pharmaceutical composition for the administration of testosterone or testosterone derivatives. The present disclosure also provides methods of treatment of diseases and disorders associated with fear and anxiety, a decrease in libido, or hypogonadism. | 2017-10-05 |
20170281645 | STEROID HORMONE PHARMACEUTICAL COMPOSITION - This disclosure provides a novel pharmaceutical composition for delivering steroid hormones to a patient in need thereof. | 2017-10-05 |
20170281646 | STEROID HORMONE PHARMACEUTICAL COMPOSITION - This disclosure provides a novel pharmaceutical composition for delivering steroid hormones, such as estradiol and progesterone, to a patient in need thereof. | 2017-10-05 |
20170281647 | STEROID HORMONE COMPOSITIONS IN MEDIUM CHAIN OILS - This disclosure provides a novel pharmaceutical composition capable of forming micelles upon exposure to the gastric environment. The pharmaceutical composition is suitable for delivering steroid hormones, and the combination of estradiol and progesterone in particular, to a subject in need thereof. | 2017-10-05 |
20170281648 | DELAYED-RELEASE GLUCOCORTICOID TREATMENT OF RHEUMATOID DISEASE - The present invention refers to the treatment of a rheumatic disease and/or osteoarthritis by administering a delayed-release dosage form of a glucocorticoid to a subject in need thereof. | 2017-10-05 |
20170281649 | COMPOUNDS AND THERAPEUTIC USES - Disclosed herein are compounds that are effective for treatment of various disease states associated with senescence. The disclosed compounds can be used to eliminate senescent cells for disease treatment. The dosing of the compounds includes both single administration and regimens of cycling dosages. | 2017-10-05 |
20170281650 | USE OF DIHYDROCHOLESTEROL - The use of dihydrocholesterol (DHC) in low doses of up to 50 mg per kg of body weight to treat or prevention excess weight or obesity and/or hyperlipidemia, and/or a disorders associated with any of the foregoing, and a composition comprising DHC. | 2017-10-05 |
20170281651 | CONCOMITANT ADMINISTRATION OF GLUCOCORTICOID RECEPTOR MODULATORS AND CYP3A OR STEROIDOGENESIS INHIBITORS - Applicant provides methods of treating diseases including Cushing's syndrome and hormone-sensitive cancers by concomitant administration of a glucocorticoid receptor antagonist (GRA) and steroidogenesis inhibitors, and by concomitant administration of a GRA and CYP3A inhibitors. Applicant provides methods of treating diseases including Cushing's syndrome and hormone-sensitive cancers by concomitant administration of mifepristone and ketoconazole. | 2017-10-05 |
20170281652 | Therapeutic Compositions and Methods - This invention relates the use of cortisol blockers (glucocorticoid receptor [GR] antagonists) for the prevention or addiction induced anxiety and withdrawal side effects as a therapeutic and in concert with a diagnostic. Such addictions could be, but are not limited to, alcohol, drugs, caffeine, sugar, food, nicotine, etc. The present invention further relates to the use of cortisol blockers (GR antagonists) for wound healing and transplants, the prevention or treatment of stress induced osteoporosis and the rapid healing of bone related injuries, and regenerative therapy. | 2017-10-05 |
20170281653 | DERMOCOSMETIC OR PHARMACEUTICAL USE OF A COMPOSITION CONTAINING AT LEAST ONE INHIBITOR OF CERTAIN CHEMOKINES - The present invention relates to the cosmetic or pharmaceutical use for a composition comprising a salicylic or nicotinic acid derivative inhibiting chemokines, for preventing or treating chronic internal and/or external inflammatory conditions. | 2017-10-05 |
20170281654 | COMPOSITIONS FOR ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING LOW BACK PAIN - Oral dosage forms of osteoclast inhibitors, such as zoledronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as chronic low back pain. | 2017-10-05 |
20170281655 | OSTEOCLAST INHIBITORS FOR KNEE CONDITIONS - Oral dosage forms of osteoclast inhibitors, such as zoledronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as knee pain. | 2017-10-05 |
20170281656 | OSTEOCLAST INHIBITORS FOR KNEE CONDITIONS - Oral dosage forms of osteoclast inhibitors, such as zoledronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as knee pain. | 2017-10-05 |
20170281657 | Low Osmolality Gel Composition - The present invention relates to polymer gel compositions and more specifically to polymer gel compositions having low osmolality for use on rectal mucosa. The present invention extends to their methods of manufacture and use, including as drug delivery vehicles and personal lubricants. | 2017-10-05 |
20170281658 | METHODS OF TREATING RETROVIRAL INFECTIONS AND RELATED DOSAGE REGIMES - The present invention relates to compounds and methods for treating retroviral infections and/or Hepatitis B viral infections. Some compounds of the invention are described by Formula I: | 2017-10-05 |
20170281659 | USE OF THIOPYRIMIDINECARBOXAMIDE FOR TREATING CANCER - There is disclosed is a method of treating disease using compound having formula SX-682 | 2017-10-05 |
20170281660 | TOPICAL COMPOSITION FOR REDUCING PATHOGEN BINDING - A method of reducing pathogen binding on skin is provided. The method includes cleaning skin with at least one of a cleanser and a sanitizer and applying a topical composition to the skin. The topical composition is comprised of one or more prebiotic and at least one carrier. | 2017-10-05 |
20170281661 | USE OF SEDOHEPTULOSE FOR PREVENTION OR TREATMENT OF INFLAMMATION - The invention discloses sedoheptulose for use in the prevention or treatment of inflammation. | 2017-10-05 |
20170281662 | POLYCARBONATES BEARING AROMATIC N-HETEROCYCLES FOR DRUG DELIVERY - Nanoparticles comprise a drug, a first block polymer and a second block polymer. The first block polymer has a poly(ethylene oxide) (PEO) block and a polycarbonate block bearing a side chain aromatic nitrogen-containing heterocycle (N-heterocycle). The N-heterocycle can be in the form of a base, a hydrosalt of the base, a sulfobetaine adduct of the base, or a combination thereof. The second block polymer has a PEO block and a polycarbonate block bearing a side chain catechol group, which can be present as a catechol, oxidized form of a catechol, and/or a polymerized form of a catechol. The nanoparticles can be dispersed in water and are capable of controlled release of the drug. | 2017-10-05 |
20170281663 | TOPICAL APPLICATION OF IVERMECTIN FOR THE TREATMENT OF DERMATOLOGICAL CONDITIONS/AFFLICTIONS - Dermatological conditions/afflictions such as rosacea, common acne, seborrheic dermatitis, perioral dermatitis, acneform rashes, transient acantholytic dermatosis, and acne necrotica miliaris, most notably rosacea, are treated by topically applying onto the affected skin area of an individual in need of such treatment, a topical pharmaceutical composition which comprises a thus effective amount of ivermectin. | 2017-10-05 |
20170281664 | TOPICAL APPLICATION OF IVERMECTIN FOR THE TREATMENT OF DERMATOLOGICAL CONDITIONS/AFFLICTIONS - Dermatological conditions/afflictions such as rosacea, common acne, seborrheic dermatitis, perioral dermatitis, acneform rashes, transient acantholytic dermatosis, and acne necrotica miliaris, most notably rosacea, are treated by topically applying onto the affected skin area of an individual in need of such treatment, a topical pharmaceutical composition which comprises a thus effective amount of ivermectin. | 2017-10-05 |
20170281665 | COMPOSITIONS INCLUDING TRICIRIBINE AND EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITOR COMPOUNDS OR SALTS THEREOF AND METHODS OF USE THEREOF - This application relates to combination therapies including triciribine compounds and epidermal growth factor receptor inhibitor compounds, particularly erlotinib-like compounds and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation. | 2017-10-05 |
20170281666 | BILAYER TABLETS OF B VITAMINS AND PROCESS FOR PREPARING THE SAME - Compositions for oral administration and processes of preparing the same are described. In particular, compositions in the form of bilayer tablets including B vitamins for modified delivery are described. The bilayer multi-B vitamin tablets offer immediate release of a first set of B vitamins, such as riboflavin (B2) and cyanocobalamin (B12) followed by controlled release of a second set of B vitamins, such as folic acid, biotin, niacinamide (B3), pyridoxine (B6), pantothenic acid (B5) and thiamine (B1). | 2017-10-05 |
20170281667 | NOVEL COMPOSITIONS AND THERAPEUTIC METHODS - The present invention is directed to novel products, variants, pharmaceutically acceptable salts and prodrugs thereof, and medical use of such compounds for the treatment and/or management of sepsis, septicemia, septic shock, ocular infection, ocular inflammation, ocular angiogenesis, rheumatoid arthritis (RA), atherosclerosis, inflammatory bowel diseases (IBD), asthma, chronic obstructive pulmonary disease, fever syndromes, cachexia, psoriasis, autoimmune diseases, cardiac diseases, retinoblastoma, cancer and/or any disorder associated with inflammation, immunomodulation and microbial infection. | 2017-10-05 |
20170281668 | MATERIALS AND METHODS FOR PREVENTING AND TREATING MICROBE-MEDIATED EPITHELIAL DISORDERS - The present invention provides pharmaceutical compositions in the form of relatively high molecular weight biocompatible polymers such as polyethylene glycol, optionally supplemented with a protective polymer such as dextran and/or essential pathogen nutrients such as L-glutamine. Also provided are methods for preventing or treating gut-derived sepsis attributable to intestinal pathogens such as | 2017-10-05 |
20170281669 | Copolymer and Method for Treatment of Bacterial Infection - A method of treatment of infection in a subject comprising administering to the subject a copolymer comprising an acrolein derived segment or a polyacrolein oligomer segment and a polyalkylene glycol oligomer segment, the copolymer having a molecular weight of no more than 1500 Daltons. | 2017-10-05 |
20170281670 | REDOX SIGNALING GEL FORMULATION - Formulations containing reactive oxygen species (ROS), processes for making these formulations, and methods of using these formulations are described. The formulations can include gels or hydrogels that contain at least one reactive oxygen species (ROS). The formulations can include a composition containing a reduced species (RS) and a reactive oxygen species (ROS). The formulations can also contain a rheology modifier and can include gels or hydrogels. Methods of preparing the formulations can include preparing a composition. Compositions can be prepared by providing water, purifying the water to produce ultra-pure water, combining sodium chloride to the ultra-pure water to create salinated water, and electrolyzing the salinated water at a temperature between about 4.5 to about 5.8° C. | 2017-10-05 |
20170281671 | NON-ANTICOAGULANT SULFATED OR SULFONATED SYNTHETIC POLYMERS - The present invention provides pharmaceutical formulations including a non-anticoagulant, non-saccharide polymer that with at least one sulfate or sulfonate moiety. The pharmaceutical formulations of the invention are of use to improve blood clotting in a subject. Also provided are useful analytical methods utilizing these polymers to query the dynamics of blood clotting in vitro. | 2017-10-05 |
20170281672 | SYSTEMS AND METHODS FOR DELIVERY OF PEPTIDES - The present invention generally relates to compositions and methods for topical or transdermal delivery. The compositions can be used in a variety of applications. In some cases, the composition may include nitric oxide and/or peptides. The nitric oxide and/or peptide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide, peptides, or both. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin. The composition can also be applied to a mucosal surface in some instances. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like. | 2017-10-05 |
20170281673 | USE OF NITRITE SALTS FOR THE TREATMENT OF CARDIOVASCULAR CONDITIONS - It has been surprisingly discovered that administration of nitrite to subjects causes a reduction in blood pressure and an increase in blood flow to tissues. The effect is particularly beneficial, for example, to tissues in regions of low oxygen tension. This discovery provides useful treatments to regulate a subject's blood pressure and blood flow, for example, by the administration of nitrite salts. Provided herein are methods of administering a pharmaceutically-acceptable nitrite salt to a subject, for treating, preventing or ameliorating a condition selected from: (a) ischemia-reperfusion injury (e.g., hepatic or cardiac or brain ischemia-reperfusion injury); (b) pulmonary hypertension (e.g., neonatal pulmonary hypertension); or (c) cerebral artery vasospasm. | 2017-10-05 |
20170281674 | Process For Generating Nanometer Sized Particles That Increase Oxygen Levels In Mammalian Tissues - A composition and process to produce poly-oxygenated metal hydroxide particles on the nanometer size scale. The relevant particle size includes all size populations ranging from 1 nanometer (nm) to 3000 nanometers (nm) or 3 micrometer (μm) in particle diameter. Filtering may be used to create homogeneous particle sizes. Exemplary delivery applications include inhalation, ingestion, anally, vaginally, dermal penetration or permeation, intramuscular injection, and intravenous injection to treat numerous conditions and diseases of mammals, including humans and animals. | 2017-10-05 |
20170281675 | Oxygen-Enabled Fluid - A colloid or crystalline solution with the addition of poly-oxygenated metal hydroxide particles. The solution is configured to treat a condition of a mammal, including a human individual and an animal including a depletion of hemoglobin and hemorrhagic shock. The solution can be intravenously administered. In some embodiments, the poly-oxygenated metal hydroxide is an aluminum poly-oxygenated hydroxide, such as Ox66™. The poly-oxygenated metal hydroxide may have particles having a diameter of less than or equal to 1 um, and specifically having a diameter of less than or equal to 100 nm. | 2017-10-05 |
20170281676 | HIV-CURE - The embodiments use an innovative approach with the goal of permanent eradication of the virus. Instead of using drugs that block different stages of the virus life cycle (which have failed to induce a permanent cure), or approaches attempting to track infected cells, the embodiments use small virucidal molecules that are known to destroy the virus in vitro and that can easily penetrate all human cells, including memory cells or other reservoir cells. The problem with the use of small molecules is their toxicity to humans or animals when administered in doses sufficient to achieve intracellular concentrations high enough to destroy the virus in all forms. The embodiments overcome these toxicities (especially the comatose state) by using a 24-hour treatment with general anesthesia, endotracheal intubation with hemodynamic support, and controlled monitored ventilation; also, a combination of these molecules are used which decreases toxicity but has additive virucidal effects. | 2017-10-05 |
20170281677 | THERAPEUTIC COMPOSITION FOR VARIOUS SKIN CONDITIONS - A therapeutic composition for various skin conditions having a mixture of at least some or all of the active ingredients, said active ingredients including clotrimazole, gentamicin, betamethasone, zinc oxide, sulfathiazole, ketoconazole, lanolin, alhucema or lavender, aloe vera, rosemary, tepezcohuite, | 2017-10-05 |
20170281678 | BOTULINUM TOXIN AND COLLOIDAL SILVER PARTICLES - Botulinum toxin is combined with colloidal silver particles to provide improved compositions for use in medical and cosmetic treatments. | 2017-10-05 |
20170281679 | METHOD FOR PREPARING UNIVERSAL PLASMA - The present invention relates to an universal plasma, originating from a mixture of plasmas originating from donor individuals of blood groups A, B, AB and/or O and compatible with all the blood groups and the preparation process thereof. | 2017-10-05 |
20170281680 | Scaffold Delivery of Immune Suppressors and Transplant Material for Control of Transplant Rejection - The present invention provides compositions, devices, and methods for the coordinated delivery of transplant material and immune suppressors for control of transplant rejection. In particular embodiments, immune suppression cells (e.g., regulatory T cells) and transplant material (e.g., cells, tissue, etc.) are provided within a delivery scaffold for transplant into a subject. | 2017-10-05 |
20170281681 | POOLED NK CELLS FROM UMBILICAL CORD BLOOD ASSOCIATED WITH ANTIBODIES AND THEIR USES FOR THE TREATMENT OF DISEASE - The invention relates to the field of cell therapy, particularly NK cell mediated therapy associated with antibodies. The present invention is directed to methods and compositions for increasing the efficiency of therapeutic natural killer cells (NK cells) and/or antibodies, wherein said methods or compositions comprise the use of pooled NK cells from umbilical cord blood units (UCBs), preferably alloreactive NK cells, in combination with a therapeutic antibody in order to enhance the efficiency of the treatment in human subjects, in particularly through an increase in antibody-dependent cell-mediated cytotoxicity (ADCC) mechanism. The present invention relates to said composition as a pharmaceutical composition, preferably for its use for the treatment of a disease in a human subject in need thereof, preferably wherein said disease is a cancer, infectious or immune disease. Finally, the present invention is also directed to a method of treatment of a disease in a human subject in need thereof, comprising the administering to said subject said pooled NK cells from UCBs, preferably alloreactive, in combination with a therapeutic antibody which can be bound to said NK cells. | 2017-10-05 |
20170281682 | CHIMERIC RECEPTORS AND USES THEREOF IN IMMUNE THERAPY - Disclosed herein are chimeric receptors comprising an extracellular domain with affinity and specific for the Fc portion of an immunoglobulin molecule (Ig), an Fc-binding domain; a transmembrane domain; at least one co-stimulatory signaling domain; and a cytoplasmic signaling domain comprising an immunoreceptor tyrosine-based activation motif (ITAM). Also provided herein are nucleic acids encoding such chimeric receptors and immune cells expressing the chimeric receptors. Such immune cells can be used to enhance antibody-dependent cell-mediated cytotoxicity and/or to enhance antibody-based immunotherapy, such as cancer immunotherapy. | 2017-10-05 |
20170281683 | GLYPICAN-3 SPECIFIC CHIMERIC ANTIGEN RECEPTORS FOR ADOPTIVE IMMUNOTHERAPY - Embodiments of the disclosure include methods and compositions related to immunotherapy that targets glypican-3. In particular embodiments, immune cells engineered to comprise a chimeric antigen receptor that targets glypican-3 are contemplated, and uses thereof. In particular embodiments, medical conditions that are associated with glypican-3 expression or an overexpression of glypican-3 are treated with GPC3 CARs. | 2017-10-05 |
20170281684 | RENAL CELL POPULATIONS AND USES THEREOF - The present invention concerns enriched heterogeneous mammalian renal cell populations characterized by biomarkers, and methods of making and using the same. | 2017-10-05 |
20170281685 | NOBLE GAS AUGMENTATION OF REGENERATIVE CELL ACTIVITY - The current invention discloses compositions of matter, therapeutic protocols, and combination therapies utilizing previously unknown activity of Xenon alone or in combination with other Noble gases to augment therapeutic activity of regenerative cells, in one embodiment said regenerative cells comprising of mesenchymal stem cells. In one embodiment the invention provides use of xenon-pretreatment of cells prior to in vivo application in order to allow for enhanced efficacy of said cells. In other embodiments xenon alone, or in combination with other gases is utilized to modulate regenerative activity of cells in vivo. | 2017-10-05 |
20170281686 | BONE MARROW STROMAL CELL DERIVED EXTRACELLULAR MATRIX PROTEIN EXTRACT AND USES THEREOF - Disclosed are bone marrow stromal cell derived extracellular matrix protein extracts that are useful for the expansion and proliferation of mesenchymal stem cells and for various therapeutic applications. | 2017-10-05 |
20170281687 | METHOD FOR CHEMOSELECTION - A method of radiation-free hematopoietic stem cell (HSC) transplantation comprises administering to a mammalian subject one or two doses of 2 to 10 mg/kg body weight of a purine base analog, such as 6TG as a pre-conditioning step. The method further comprises engrafting into the subject hypoxanthine-guanine phosphoribosyltransferase (HPRT)-deficient donor HSCs within 48 to 72 hours of the pre-conditioning step; and administering to the subject about 1 to 5 mg/kg of the purine base analog every two to four days for two to eight weeks following the engrafting step. The method is performed in the absence of pre-conditioning via radiation. The subject is therefore not treated with myeloablative radiation in preparation for transplantation, and thus the subject is free of myeloablative radiation-induced toxicity. | 2017-10-05 |
20170281688 | SYNTHETIC RHINOCEROS HORN ANALOGUES - Rhinoceros horn analogues and methods of synthesis thereof. Compounds with medicinal effects can be incorporated into the analogues. Genetic fingerprints can also be incorporated into the analogues. The analogues can be formulated into compositions. | 2017-10-05 |
20170281689 | FISH OIL TOPICAL COMPOSITION - Disclosed is a method of reducing the rancid fish odor smell in a topical composition comprised of fish oil which comprises mixing the composition with monolaurin. Also disclosed are various anhydrous topical compositions comprising fish oil. One comprises fish oil, cetyl ester, palm olein, medium-chain triglyceride(s) of a mixture of C8 and C10 fatty acids, mixture of C8/C10 fatty acids, and monolaurin, another one comprises fish oil, cetyl ester, palm olein, medium-chain triglyceride(s) of a mixture of C8 and C10 fatty acids, mixture of C8/C10 fatty acids, monolaurin, collagen and sea salt, an a third one comprises fish oil, cetyl ester, palm olein, medium-chain triglyceride(s) of a mixture of C8 and C10 fatty acids, mixture of C8/C10 fatty acids, monolaurin and hydrocolloid. These compositions are useful for treating wounds and skin conditions. | 2017-10-05 |
20170281690 | PHARMACEUTICAL COMPOSITION FOR PREVENTING, TREATING AND CURING ROSACEA, COMPRISING SNAIL SLIME, CHAMOMILE AND PROPOLIS - The invention relates to a pharmaceutical composition consisting of snail slime | 2017-10-05 |
20170281691 | METHODS FOR CONSTRUCTING ANTIBIOTIC RESISTANCE FREE VACCINES - The present invention provides | 2017-10-05 |
20170281692 | MICROBIOTA RESTORATION THERAPY (MRT), COMPOSITIONS AND METHODS OF MANUFACTURE - Microbiota restoration therapy compositions and methods for manufacturing, processing, and/or delivering microbiota restoration therapy compositions are disclosed. An example method for manufacturing a microbiota restoration therapy composition may include collecting a human fecal sample and adding a diluent to the human fecal sample to form a diluted sample. The diluent may include a cryoprotectant. The method may also include mixing the diluted sample with a mixing apparatus and filtering the diluted sample. Filtering may form a filtrate. The method may also include transferring the filtrate to a sample bag and sealing the sample bag. | 2017-10-05 |
20170281693 | MICROBIOTA RESTORATION THERAPY (MRT), COMPOSITIONS AND METHODS OF MANUFACTURE - Microbiota restoration therapy compositions and methods for manufacturing, processing, and/or delivering microbiota restoration therapy compositions are disclosed. An example method for manufacturing a microbiota restoration therapy composition may include collecting a human fecal sample and adding a diluent to the human fecal sample to form a diluted sample. The diluent may include a cryoprotectant. The method may also include mixing the diluted sample with a mixing apparatus and filtering the diluted sample. Filtering may form a filtrate. The method may also include transferring the filtrate to a sample bag and sealing the sample bag. | 2017-10-05 |
20170281694 | TOPICAL CLEANSING COMPOSITION WITH PREBIOTIC/PROBIOTIC ADDITIVE - A topical cleansing composition is disclosed that includes an active ingredient, comprising one or more of a probiotic, a probiotic derivative, and prebiotic, a humectant, one or more surfactants; and water. Topical cleansing composition reduces pathogen binding on skin by a statistically significant amount, as compared to an otherwise identical topical composition without the active ingredient. | 2017-10-05 |
20170281695 | SANITIZER COMPOSITION WITH PROBIOTIC/PREBIOTIC ACTIVE INGREDIENT - A topical sanitizing composition for restoring skin's natural balance of bacteria is provided. The topical sanitizing composition includes about 0.02 wt. % to 10.0 wt. % of an active ingredient, at least about 40 wt. % of one or more C | 2017-10-05 |
20170281696 | Nutrient Rich Germinant Composition and Spore Incubation Method - A nutrient-germinant composition to aid in spore germination and a method for increased spore germination efficiency. The composition comprises L-amino acids, D-glucose and/or D-fructose, a phosphate buffer, an industrial preservative, and may include bacteria spores or they may be separately combined for germination. The method comprises providing a nutrient-germinant composition and bacteria spores, preferably of one or more | 2017-10-05 |
20170281697 | PHARMACEUTICAL COMPOSITION CONTAINING COMBINATIONS OF VITAMINS, MINERALS, PROBIOTICS, AND PREBIOTICS EFFECTIVE IN PREVENTING ADVERSE EFFECTS ASSOCIATED WITH THE USE OF PROTON-PUMP INHIBITORS - The present invention relates to a pharmaceutical composition containing a combination of vitamins, specific salts of calcium, magnesium, and iron, probiotics and prebiotics, which prevents the occurrence of adverse effects associated with long-term use of proton-pump inhibitors (PPIs). This effect is achieved by restoring all nutrient deficiencies and rectifying the intestinal flora imbalance caused by this type of drugs, particularly in patients with gastroesophageal reflux disease and Zollinger-Ellison syndrome. | 2017-10-05 |
20170281698 | Method and Composition for Inhibiting Bacterial Adhesion of Oral Pathogens - A method for inhibiting bacterial adhesion of oral pathogens, comprising administering a heat-inactivated | 2017-10-05 |
20170281699 | METHOD OF IDENTIFYING A BIOLOGICALLY-ACTIVE COMPOSITION FROM A BIOFILM - The subject invention provides materials and methods that effectively support innate immunity and/or disperse pathogenic biofilms using readily available, nontoxic, natural substances, while supporting restoration of normal microbiotic homeostasis. In one embodiment, the subject invention provides anti-biofilm compositions comprising one or more probiotic organisms, anti-microbial honey, and other ingredients such as prebiotic compounds, other hive products, green tea derivatives, other plant derivatives, and vitamin D3. | 2017-10-05 |
20170281700 | PHAGE THERAPY FOR TARGETING ENTEROCOCCI - Isolated bacteriophages having genomes comprising the nucleic acid sequences as set forth in SEQ ID NOs: 1 and 2, or variants thereof, and compositions comprising the bacteriophages in a ratio ranging from 1:10 to 10:1, respectively. Further provided are uses of the compositions in treating or preventing an infection inflicted by a bacteria (e.g., | 2017-10-05 |
20170281701 | Formulation for the Nebulization of Oil Based Substances Suitable for Use with a Vibrating Mesh Nebulizer - Several variations of formulations are used as a water base solution to disperse oil soluble pharmaceuticals, including cannabis extract, suitable for use with a VMN. Common elements include added small amount of sodium electrolytes to facilitate the nebulization process and ethanol in controlled amount as needed to dilute or dissolve thick waxy substances such as found in some cannabis extracts. Surfactants, co-surfactants and/or emulsifiers to include but not limited to Acconon™, ethanol, hydroxylated soy lecithin and/or sodium lauryl sulfate are used. The ingredients are sonicated to obtain a uniform respirable liposomal suspension that could be delivered in low micron range using a VMN for efficient absorption into the blood stream by oral inhalation. | 2017-10-05 |
20170281702 | METHOD OF ISOLATING ANTI-VIRAL INGREDIENTS FROM BAPHICACANTHUS CUSIA, COMPOSITIONS COMPRISING THEM AND THEIR MEDICAL USE - The present invention provides a method of isolating at least one ingredient with anti-viral efficacy from | 2017-10-05 |
20170281703 | NUTRITIONAL SUPPLEMENT AND RELATED METHOD FOR ACTIVATING A SUBJECT'S ANTIOXIDANT SYSTEM - A nutritional supplement comprises components (A), (B) and (C), and optionally, additional component(s) (D). The nutritional supplement can activate a subject's antioxidant system, more specifically the subject's antioxidant response element (ARE). In one embodiment, the nutritional supplement comprises: (A) glabridin; (B) licochalcone A; and (C) licorice root flavonoids. In another, the nutritional supplement comprises: (A) a first licorice root extract comprising glabridin; (B) a second licorice root extract comprising licochalcone A; and (C) a third licorice root extract comprising flavonoids. Components (A), (B) and (C) are in a combined amount sufficient to activate the subject's antioxidant system after ingestion. In addition, components (A), (B) and (C) are present in a weight ratio (A:B:C) such that their combined effect is greater than the sum of their separate effects regarding activation of the subject's antioxidant system after ingestion of the nutritional supplement. | 2017-10-05 |
20170281704 | ANTI DENGUE ACTIVITY OF CISSAMPELOS PAREIRA EXTRACTS - The present invention relates to the anti dengue activity of the | 2017-10-05 |
20170281705 | ANTI-VIRAL THERAPEUTIC COMPOSITIONS - The invention discloses an anti-viral therapeutic composition, which includes at least one anti-viral active ingredient originating from an aqueous Buchu extract or bio-active fraction thereof in a pharmaceutically acceptable form. The composition can be a pharmaceutical composition including a therapeutically effective amount of at least one or more anti-viral active ingredient and one or more pharmaceutically acceptable carriers or additives. The aqueous Buchu extract is obtained from the species | 2017-10-05 |
20170281706 | Sugar Extract - This invention relates to novel extracts from sugar cane and sugar beet molasses and the characterisation of those extracts. The extracts are enriched in hydrophobic compounds including polyphenols, in levels 5 to 10 fold higher than found in molasses itself Methods for extracting the extract are also described, together with new uses for the extracts as food ingredients, food modifiers and therapeutic substances. | 2017-10-05 |
20170281707 | Composition and Method for the Treatment of Menopause - Provided herein are compositions comprising an herbal extract of a mixture of Radix Rehmanniae, Fructus | 2017-10-05 |
20170281708 | COMBINATIONS OF EXTRACTS OF SERENOA REPENS AND LIPOPHILIC EXTRACTS OF ZINGIBER OFFICINALIS AND ECHINACEA ANGUSTIFOLIA, THE USE THEREOF, AND FORMULATIONS CONTAINING THEM - Disclosed are compositions containing an extract of | 2017-10-05 |
20170281709 | PEPTIDE CONJUGATES OF GLP-1 RECEPTOR AGONISTS AND GASTRIN AND THEIR USE - The present invention relates, inter alia, to certain peptide conjugates, and to the use of the conjugates in the treatment of a variety of diseases or disorders, including diabetes (type 1 and/or type 2) and diabetes related diseases or disorders. | 2017-10-05 |
20170281710 | USE OF INHIBITORS OF BINDING BETWEEN A PAR-1 RECEPTOR AND ITS LIGANDS FOR THE TREATMENT OF GLIOMA - The present invention relates to a method of treating glioma in a subject. The method comprises selecting a subject having a glioma, providing an inhibitor of binding between a PAR-1 receptor and a ligand of the PAR-1 receptor, and administering the inhibitor to the selected subject under conditions effective to treat the glioma and/or prevent spread of tumor cells. Methods for inhibiting proliferation of glioma cells and/or precursors thereof and a method of screening for compounds suitable for treating glioma in subjects are also disclosed. | 2017-10-05 |
20170281711 | Activin Type 2 Receptor Binding Proteins and Uses Thereof - This disclosure provides ActRII-binding proteins such as anti-ActRIIA and anti-ActRIIB antibodies, and compositions and methods for making the ActRII-binding proteins. In certain aspects the ActRII-binding proteins inhibit, or antagonize ActRII activity. In addition, the disclosure provides compositions and methods for diagnosing and treating diseases and conditions associated muscle wasting; a fibrotic condition; an inflammatory, cardiovascular, pulmonary, musculoskeletal, neurologic, ocular, skeletal, autoimmune, or metabolic disease or condition; wound healing; and cancer, and other ActRII-mediated diseases and conditions. | 2017-10-05 |
20170281712 | COMPOSITIONS AND METHODS FOR CHRONIC USE OF A WEIGHT-GAINING COMPOUND - Provided herein is a method of binding growth hormone secretagogue receptors in one or more companion animals or livestock to stimulate hunger independent of release of growth hormone. The method can provide administering a therapeutically effective amount of a capromorelin-containing composition to a companion animal or livestock in need thereof for a period of at least 30 days. Optionally, one or more flavoring agents or flavor-masking agents can be added to the capromorelin-containing composition to enhance or mask the flavoring of the composition for the companion animal or livestock. | 2017-10-05 |
20170281713 | A METHOD FOR SIDE EFFECT REDUCTION IN THE USE OF STATINS VIA PHYSIOLOGICALLY SYNTHESIZED GLUTATHIONE - Embodiments of the present invention relate generally the use of certain compositions, e.g., compositions comprising a glutathione precursor and a selenium source, in the therapy of subjects suffering from diseases associated with hyperiipidemia and/or hypercholesterolemia. Related embodiments of the present invention relate to treatment and/or reducing the incidence of the side effects of statin therapy comprising administering to a subject in need, a composition comprising a glutathione precursor and a selenium source. Embodiments of the invention also relate to the use of the compositions in combination therapy with other agents such as statins, cholesterol absorption inhibitors, bile acid binding resins, or fibrates. In other embodiments, the invention relates to the use of such compositions comprising the glutathione precursor and the selenium source in the therapy of subjects suffering from erectile dysfunction and/or viral diseases such as Ebola virus disease (EVD) or Ebola hemorrhagic fever (EHF). | 2017-10-05 |
20170281714 | METHOD OF TREATMENT USING LIPOSOMALLY FORMULATED REDUCED GLUTATHIONE TO COOPERATE WITH IL-10 TO MODULATE INFLAMMATORY RESPONSE TRIGGERED IN HIV+ AND TB IMMUNE-COMPROMISED DIABETIC PATIENTS - In the setting of chronic infection with a pathogen, the immune system must adapt to the ongoing presence of inflammatory responses driven by the pathogen in order to control the replication of the infecting agent at an acceptable level while limiting immune-mediated damage (immunopathology) (1). A complex interaction is required to accomplish this using a balance of immune related cytokines to stimulate and control the immune response. A particular formulation of reduced glutathione of high concentration in a liposome is proposed. In cooperation with the immune system, the liposomally formulated reduced glutathione according to the invention surprisingly achieves the balance between over-reduction of IL-10 and its necessary bodily function and signaling. | 2017-10-05 |